Another response to RDUNN's BS (and also where Le
Post# of 72447
(Total Views: 187)
Posted On: 01/12/2018 9:24:04 AM
Another response to RDUNN's BS (and also where Leo can find more funding with minimal dilution)
Rdunn88 Thursday, 01/11/18 08:03:13 PM
Re: DaubersUP post# 212472
Post #
212479
of 212533 Go
Sure, IPIX can run their own phase 3’s? Ok, if that’s the case go for it.... stop wasting time searching for partners.
Tap Aspire for 50 million more and move science along. First up absssi followed by UP/OM/P and K.
keltoi Friday, 01/12/18 09:18:43 AM
Re: DaubersUP post# 212472
Post #
212536
of 212536 Go
People seem to forget that some of the "Low hanging fruit" comes with Priority Review qualifications:Moving either one
of these (K for Ped.Retinoblastoma or BOM) would generate 100's of millions in Priority Review Voucher sales to other
Pharmas.
http://www.ipharminc.com/press-release/2016/1...om-fda-for
-kevetrin-for-the-treatment-of-retinoblastoma?rq=priority%
“Receiving the Rare Pediatric Disease designation strengthens our portfolio and adds to our belief that Kevetrin has
the potential to provide a meaningful therapeutic benefit to children and families affected by retinoblastoma, where
enucleation (removal) of the eye is often the only solution,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “We are putting plans in place to move ahead with this exciting project. We view the voucher program as very valuable in meeting areas of unmet medical need and certainly keep in mind the monetary component considering United Therapeutics recently agreed to sell its Rare Pediatric Disease Priority Review Voucher to a subsidiary of AbbVie for $350 million.”
http://www.ipharminc.com/press-release/2016/1...in-om-for-
oral-mucositis?rq=priority%20review
The FDA established the Fast Track Designation process to facilitate the development, and expedite the review of, drugs
that have the potential to treat serious and life threatening conditions and fill an unmet medical need. Drugs developed
under the Fast Track program are afforded increased access to the FDA and could qualify for other programs to expedite
development, including priority review and accelerated approval.
Kelt
Rdunn88 Thursday, 01/11/18 08:03:13 PM
Re: DaubersUP post# 212472
Post #
212479
of 212533 Go
Sure, IPIX can run their own phase 3’s? Ok, if that’s the case go for it.... stop wasting time searching for partners.
Tap Aspire for 50 million more and move science along. First up absssi followed by UP/OM/P and K.
keltoi Friday, 01/12/18 09:18:43 AM
Re: DaubersUP post# 212472
Post #
212536
of 212536 Go
People seem to forget that some of the "Low hanging fruit" comes with Priority Review qualifications:Moving either one
of these (K for Ped.Retinoblastoma or BOM) would generate 100's of millions in Priority Review Voucher sales to other
Pharmas.
http://www.ipharminc.com/press-release/2016/1...om-fda-for
-kevetrin-for-the-treatment-of-retinoblastoma?rq=priority%
“Receiving the Rare Pediatric Disease designation strengthens our portfolio and adds to our belief that Kevetrin has
the potential to provide a meaningful therapeutic benefit to children and families affected by retinoblastoma, where
enucleation (removal) of the eye is often the only solution,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “We are putting plans in place to move ahead with this exciting project. We view the voucher program as very valuable in meeting areas of unmet medical need and certainly keep in mind the monetary component considering United Therapeutics recently agreed to sell its Rare Pediatric Disease Priority Review Voucher to a subsidiary of AbbVie for $350 million.”
http://www.ipharminc.com/press-release/2016/1...in-om-for-
oral-mucositis?rq=priority%20review
The FDA established the Fast Track Designation process to facilitate the development, and expedite the review of, drugs
that have the potential to treat serious and life threatening conditions and fill an unmet medical need. Drugs developed
under the Fast Track program are afforded increased access to the FDA and could qualify for other programs to expedite
development, including priority review and accelerated approval.
Kelt
(0)
(0)